Skip to main content
    L

    Lantern Pharma Inc (LTRN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    -0.04 (-10.18%)

    Market Cap: $6.47M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    80%(20/25)
    Avg Surprise
    +12.09%
    Streak
    6 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.42
    RangeN/A
    3 analysts
    Revenue Consensus
    N/A
    RangeN/A
    3 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-400.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.96xQuick Ratio1.96x
    Trading Statistics
    Beta2.46Avg Volume264.21K
    52-Week High$4.3452-Week Low$0.42

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 59.3% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 24.9, below 30, the oversold line.

    Moving Averages

    SMA 10$0.51
    SMA 20$0.59
    SMA 50$0.95
    SMA 200$2.31
    EMA 10$0.50
    EMA 20$0.60
    EMA 50$1.00
    EMA 200$2.16

    MACD

    Line: -0.15Signal: -0.16Hist: 0.01

    ADX

    ADX: 47.8+DI: 9.8-DI: 32.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$0.64

    Bollinger Bands

    Upper Band$0.79
    Lower Band$0.39
    %B Position6896%(Upper)
    Band Width0.01

    RSI (14-Day)

    Oversold
    24.9

    Momentum Oscillators

    Stoch %K2.3
    Stoch %D3.8
    Williams %R-98.5
    ROC (10d)-39.2%
    Momentum-0.25
    CCI (20d)-156.1
    MFI (14d)43.4

    Volatility Measures

    ATR (14d)$0.10(25.5%)
    StdDev (20d)0.10
    Hist Vol138.6%(High)

    Volume Flow

    VWAP$0.42
    OBV18.3M
    AD Line-28.2M
    CMF (20d)-0.292

    Volume Metrics

    Avg Vol (20d)272.1K
    Vol Ratio0.7x
    VWMA (20d)$0.62

    Pivot Points

    R3$0.49
    R2$0.48
    R1$0.45
    Pivot Point$0.44
    S1$0.42
    S2$0.40
    S3$0.38

    Advanced Oscillators

    TSI-45.20
    Ultimate Osc27.1
    KST-388.61

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about LTRN

    News

    LTRN Valuation

    LTRN Profitability: Margins, ROIC and FCF

    Lantern Pharma (LTRN) has an operating margin of 0.0% and a net margin of 0.0%.

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -400.9%
    LTRN financial statements

    Lantern Pharma Competitors

    The companies most similar to Lantern Pharma (LTRN) include Liminatus Pharma, Inc. Class A Common Stock, CNS Pharmaceuticals and Processa Pharmaceuticals.

    Sector: Healthcare

    Companies most similar to Lantern Pharma

    LTRN Bull Case vs Bear Case

    Bull case

    • LTRN beat EPS estimates in 87.5% of its last 8 reported quarters.

    LTRN Earnings: Beat Rate and Next Report

    Lantern Pharma (LTRN) beat the EPS estimate in 7 of the last 8 quarters (87.5%). Its next report is expected on Nov 17, 2026.

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    15.0%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$0.42
    LTRN earnings history

    LTRN Earnings Date

    LTRN reports Nov 17, 2026. The date is estimated.

    LTRN Earnings Call

    The latest LTRN earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    LTRN ETF Holders

    See insider activity

    Updated Aug 14, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About LTRN

    When does LTRN report earnings?

    Lantern Pharma Inc (LTRN) is expected to report earnings on Nov 17, 2026.

    Does LTRN pay dividends?

    Lantern Pharma Inc (LTRN) does not currently pay a regular dividend.

    What is LTRN's market cap?

    Lantern Pharma Inc (LTRN) has a market capitalization of $6.47M with a current stock price of $0.39.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.